An update from Bristol-Myers Squibb ( (BMY) ) is now available.
On May 6, 2025, Bristol-Myers Squibb held its Annual Meeting, where shareholders elected 11 directors to serve until the 2026 meeting. Key decisions included the approval of executive compensation and the ratification of Deloitte & Touche LLP as the independent accounting firm for 2025. However, shareholder proposals on Corporate Financial Sustainability and ceasing DEI efforts were not approved.
Spark’s Take on BMY Stock
According to Spark, TipRanks’ AI Analyst, BMY is a Neutral.
Bristol-Myers Squibb’s overall stock score reflects strong financial performance, particularly in cash flow generation and gross profitability. The recent earnings call provided positive revenue and EPS guidance, supporting a strong outlook. However, technical indicators show bearish momentum, and some regulatory and trial challenges persist. The balanced valuation and attractive dividend yield provide additional support.
To see Spark’s full report on BMY stock, click here.
More about Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company operates in the pharmaceutical industry, primarily producing drugs for oncology, cardiovascular, and immunology sectors.
Average Trading Volume: 13,831,310
Technical Sentiment Signal: Sell
Current Market Cap: $96.81B
For a thorough assessment of BMY stock, go to TipRanks’ Stock Analysis page.